ࡱ >
\ p None B a = c @ = Z ?N*8 X" 1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial General ` { Table_1 H 0 Patient
Lesion Specific therapy( Progression-freeinterval (months)' Lesion size beforetreatment (cm)7 Lesion size after twocycles of chemotherapy (cm) 1 Cisplatin/Platinol 4 4.4 1.8 2) Carboplatin/Paraplatin+Gemcitabine/Gemzaru * 5.8 5.0 3 Erlotinib/Tarceva 21 1.9 0.7( Carboplatin/Paraplatin+Pemetrexed/Alimta 12 3.2 2.9 5% Cisplatin/Platinol+Gemcitabine/Gemzar 6.2 5.3 6$ Cisplatin/Platinol+Pemetrexed/Alimta 14 2.1 1.7 7 10 2.7 2.5 8 9.3 7.3 1.4 0.8 9 3.5 2.8 1.6 1.5
d MbP?_ % * + &P &F